- Global Pharma News & Resources

Kite, a Gilead Company, to present latest cell therapy research at 24th Congress of the European Hematology Association (EHA), Amsterdam, The Netherlands

  • Kite, a Gilead Company, is pleased to support the 24th Congress of the European Hematology Association, taking place from 13-16 June 2019 in Amsterdam, The Netherlands.
  • The meeting will bring together experts from around the world to present new clinical research, exchange knowledge and discuss the latest innovations in the diagnosis and treatment of haematological diseases.
  • Kite will present the latest scientific data from its cell therapy research programmes in haematological cancers, providing new insights to attending European experts.
  • The company will also host two scientific symposia with leading experts in the field of cell therapy:
    • Beyond clinical trials in B-cell malignancies: what real-world evidence tells us (Thursday 13 June, 10:15 – 11:45 CET, Hall 3B)
    • A patient-centric approach to CAR T therapy: from treatment selection to patient management (Thursday 13 June, 17:00 – 18:30 CET, Elicium 1)

“We look forward to contributing towards discussions with leading experts at this year’s EHA congress, one of the most important global forums in haematology,” said Dominique Tonelli, MD, Head of Medical Affairs, Europe, Kite. “Kite remains committed to advancing the treatment of challenging haematological cancers through innovative cell therapies.”

Key presentations at the meeting will include:

Presentation Number and Date/Time (CET)  Abstract Title

Abstract #PS1066 (Poster)

Saturday 15th June 2019 (17:30 – 19:00)

Axicabtagene Ciloleucel (axi-cel) in Refractory Large B Cell Lymphoma: Outcomes in Patients ≥ or < 65 Years of Age in the Pivotal Phase 1/2 ZUMA-1 Study

Abstract #PS1067 (Poster)

Saturday 15th June 2019 (17:30 – 19:00)

Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma: Preliminary Results of Earlier Steroid Use

Abstract #PS945 (Poster)

Saturday 15th June 2019 (17:30 – 19:00)

KTE-X19, An Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: End of Phase 1 Results of ZUMA-3

Abstract #PS962 (Poster)

Saturday 15th June 2019 (17:30 – 19:00)

Phase 1 Results of ZUMA-4: KTE-X19, an anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Pediatric and Adolescent Patients with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

In August 2018, axicabtagene ciloleucel, a CAR T cell therapy, received European Marketing Authorisation for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.1

The following experts will be available for comment on Kite activities at the meeting:

  • Prof. Marie José Kersten, Head of the Department of Hematology at the Academic Medical Center (AMC), Amsterdam
  • Dr. Max Topp, MD, Professor and Head of Haematology, University Hospital of Wuerzburg, Germany
  • Dominique Tonelli, Head of Medical Affairs Europe, Kite
  • Dick Sundh, Head of Europe, Kite

For more information or to arrange an interview please contact Cressida Robson, Media (Europe), Gilead (+44 7341 789 204 or

Editor Details

  • Company:
    • pharmiweb
  • Name:
    • Mike Wood
Last Updated: 06-Jun-2019